NRx Pharmaceuticals (NRXP)
(Delayed Data from NSDQ)
$1.19 USD
-0.02 (-1.65%)
Updated Dec 11, 2024 04:00 PM ET
After-Market: $1.17 -0.02 (-1.68%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.19 USD
-0.02 (-1.65%)
Updated Dec 11, 2024 04:00 PM ET
After-Market: $1.17 -0.02 (-1.68%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth A Momentum B VGM
Zacks News
NRx Pharmaceuticals (NRXP) Upgraded to Buy: Here's Why
by Zacks Equity Research
NRx Pharmaceuticals (NRXP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
The latest trading day saw NRx Pharmaceuticals, Inc. (NRXP) settling at $3.14, representing a +0.64% change from its previous close.
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, NRx Pharmaceuticals, Inc. (NRXP) closed at $3.04, indicating a +0.66% shift from the previous trading day.
NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
NRx Pharmaceuticals (NRXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for April 4th
by Zacks Equity Research
DELL, NRXP, STEP, TCOM and PARAA have been added to the Zacks Rank #1 (Strong Buy) List on April 4, 2023.
Pick These Top-Ranked Stocks to Deck Up Your Christmas Tree
by Sweta Killa
We have crafted a tree with the most flourishing stocks of 2023 and the ones that are poised to soar in 2024.
NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up
by Zacks Equity Research
NRx Pharma (NRXP) receives FDA clearance to begin clinical development for its lead candidate, NRX-101, to treat chronic pain.
All You Need to Know About NRx Pharmaceuticals, Inc. (NRXP) Rating Upgrade to Buy
by Zacks Equity Research
NRx Pharmaceuticals, Inc. (NRXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Company News for Dec 30, 2021
by Zacks Equity Research
Companies in The News Are: FCEL,CALM,NRXP,AAPL
Company News for Nov 30, 2021
by Zacks Equity Research
Companies in the news are: KRYS, ADGI, NRXP, HTZ
IQVIA (IQV) Announces Collaboration With NRx Pharmaceuticals
by Zacks Equity Research
IQVIA (IQV) and NRx are set to work closely to support activities essential for emergency use authorization of ZYESAMI.